Skip to main content
DBV Technologies logo

DBV Technologies - Investor Relations & Filings

Listed IPO Mar 2012
Ticker · DBV ISIN · FR0010417345 LEI · 969500PVBQFWQKVDMD80 PA Manufacturing
Filings indexed 1,625 across all filing types
Latest filing 2026-01-08 Major Shareholding Noti…
Country FR France
Listing PA DBV · 7 venues

About DBV Technologies

https://www.dbv-technologies.com/

DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-08 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-07 English
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Regulatory Filings
2026-01-07 French
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-12-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.